Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people starting tirzepatide notice a restless, on-edge feeling in the first few weeks, and it raises an understandable question: is Mounjaro the reason? Anxiety is not listed as a common side effect in the Mounjaro prescribing information, but the hormonal shifts, blood-sugar fluctuations, and physical sensations that come with early treatment can all produce feelings that closely resemble anxiety. Understanding what is actually happening makes it a lot easier to manage. These are prescription-only medicines, and any new or persistent psychological symptoms should be discussed with your prescribing team before you change how you are using your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It tends to arrive quietly: a background hum of unease, a heart that feels slightly too quick, difficulty settling at night. For many people, this happens within 24 to 48 hours of their first Mounjaro dose or a dose increase, and the timing is not coincidental. Tirzepatide activates both GIP and GLP-1 receptors, the only licensed weight-loss medicine in the UK to work on both pathways simultaneously. GLP-1 receptors exist not just in the gut but in the brain's regions involved in appetite regulation and stress signalling. When those receptors are activated for the first time, some people notice a heightened sense of alertness or physical arousal that their brain can interpret as anxiety, even though no psychological trigger is present.
Added to that, tirzepatide slows gastric emptying and reduces appetite significantly. If you are eating considerably less than usual without adjusting what you eat, a drop in blood glucose (even a mild one) produces adrenaline as the body's corrective response. Adrenaline causes exactly the symptoms most people call anxiety: a racing pulse, shallow breathing, restlessness, a sense that something is wrong. The NHS medicines guidance for tirzepatide notes dizziness and headache among the common early effects, and these same mechanisms are likely contributors. You can read the NHS patient information on tirzepatide for a full picture of what is recognised in the prescribing evidence.
The reassuring part is that this pattern is dose-dependent and time-limited for most people. The 2.5mg starting dose exists precisely to let your system adjust before any therapeutic increase, and the sensations tend to settle considerably within two to three weeks.
The gut-brain axis is not a metaphor. GLP-1 receptors in the vagus nerve pathway carry signals directly between the digestive system and regions of the brain involved in mood, reward, and stress. When tirzepatide engages those receptors, particularly at higher doses, the cascade of signals can produce effects that are not purely digestive. A question our prescribers hear most weeks is some version of: "I feel anxious, but nothing in my life has changed, could the injection be doing this?" If you have been asking yourself whether Mounjaro can cause anxiety, the honest answer is that it is unlikely to trigger clinical anxiety as a direct pharmacological effect, but it can absolutely produce physical sensations that the brain reads as anxious arousal, especially in people who are already prone to health-focused worry or who have had anxiety in the past.
There is also a practical, situational layer. Starting a new injectable treatment, monitoring your weight, and adjusting your eating habits all create a background of self-scrutiny that can heighten awareness of bodily sensations. People sometimes notice a rapid heartbeat that they might normally have ignored. They attribute it to the pen. That attribution is not wrong exactly, the raised vigilance and the changed physiology interact. Understanding both layers usually helps more than dismissing either one. For a fuller look at how Mounjaro affects the body and what the known Mounjaro side effects involve, our detailed overview covers the evidence across the whole profile.
Nausea is the most commonly reported early effect of tirzepatide, affecting a substantial proportion of people in the first weeks of treatment, per the SURMOUNT-1 trial data published in the New England Journal of Medicine. Nausea itself can produce secondary anxiety: the body's threat-detection system treats persistent gastric distress as a warning signal, triggering low-level fight-or-flight responses. People who feel nauseated often breathe shallowly, tense their abdomen, and avoid food in ways that compound blood-sugar instability. The result can feel remarkably like a panic response.
If you are experiencing this, small but regular protein-containing meals, adequate hydration, and avoiding lying down immediately after eating can reduce both the nausea and the secondary anxious sensations. These are the kinds of practical steps that come up naturally in a clinical review, and they are discussed in detail on our Mounjaro information page. Worth knowing: the MHRA keeps an ongoing watch on the psychological effects of GLP-1 medicines and you can report any suspected side effects (including mood changes) directly via the Yellow Card scheme.
The distinction between transient physical sensations and genuine psychological deterioration matters. Feelings of unease that arrive with nausea after a dose and fade over a few days are part of the adjustment period most people navigate without stopping treatment. Our guidance on Mounjaro and anxiety goes into more detail on how to tell whether what you are experiencing sits within the expected adjustment period or warrants closer attention, including what worsening week on week or low mood alongside anxiety may indicate. That pattern warrants a conversation with your prescriber before your next dose, not a wait-and-see approach.
Pre-existing anxiety or depression is not an absolute contraindication for tirzepatide, but it is exactly the kind of clinical detail a prescriber needs to know at consultation and to monitor through follow-up. At nume, our clinical team reviews every case personally (not via an automated decision tool) and aftercare is available seven days a week so that questions like this do not have to wait until a scheduled review.
If you are trying to understand whether tirzepatide is the right option given your mental health history, the first step is a clinical assessment rather than a Google search. You can check your eligibility through our free consultation, and our prescribers will take the full picture into account. Some people also ask whether bruising is a side effect of Mounjaro, particularly if they notice skin changes at the injection site alongside other early reactions, and our dedicated page addresses that question with the available evidence. For context on the cost of Mounjaro treatment privately, our pricing page sets out what is included in a single transparent fee.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.